Both the biological target and the molecules were discovered using AI.
AI delivers a patentable small molecule preclinical candidate for a new target with demonstrated efficacy in both human patient cells and animal models for Idiopathic Pulmonary Fibrosis (IPF) in less than 18 months.
No comments:
Post a Comment